-
Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression
19 Apr 2024 04:41 GMT
In a recent study published in the journal Nature Medicine, a large, international team of researchers conducted an exploratory analysis to evaluate whether the monoclonal antibody prasinezumab, which had previously been observed to be effective in slowing …
-
Cerevel's Parkinson's disease drug improves symptom control in late-stage trial
19 Apr 2024 02:04 GMT
London: Cerevel Therapeutics said on Thursday its Parkinson's disease drug improved symptom control in patients when tested as an add-on therapy, meeting the main goal in a late-stage study.
The trial, which enrolled 507 adults, tested Cerevel's …
-
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
18 Apr 2024 20:30 GMT
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's …
-
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
18 Apr 2024 17:54 GMT
On Thursday, Cerevel Therapeutics Holdings Inc. CERE released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease.
The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive …
-
AI Identifies New Potential Treatments For Parkinson’s Disease
18 Apr 2024 17:08 GMT
AI has been used to identify potential new drugs for Parkinson's Disease.getty
A new artificial intelligence (AI) based strategy has significantly sped up the identification of potential new drugs to treat Parkinson's disease. The work, published …
-
Sage Therapeutics Tanks 29% After Parkinson's Treatment Fails Mid-stage Study
17 Apr 2024 15:13 GMT
Shares of Sage Therapeutics, Inc. (SAGE) tanked 29% on Wednesday after its Parkinson's treatment failed in a mid-stage study.
SAGE is currently trading at $11.19, down $4.44 or 28.48%, on the Nasdaq. The stock began trading at $12.96 after closing …
-
Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade)
18 Apr 2024 12:28 GMT
Richard Drury/DigitalVision via Getty Images Sage Therapeutics Faces Setbacks with Dalzanemdor Failure Sage Therapeutics' (NASDAQ:SAGE) stock is down 27% since my "Strong Sell" recommendation last November. At the time, I voiced concerns …
-
Drugs Like Ozempic And Mounjaro Could Treat Other Conditions—Here’s What Scientists Are Looking At
18 Apr 2024 12:14 GMT
Topline
Weight loss and diabetes may just be the beginning for drugs like Ozempic, Wegovy, Mounjaro and Zepbound as reports increasingly suggest they may have far-reaching benefits for treating conditions as diverse as heart and liver disease, Parkinson’s, …
-
Cerevel notches Phase 3 Parkinson's win ahead of AbbVie transaction closing
18 Apr 2024 11:00 GMT
As it waits for its acquisition by AbbVie to finalize, Cerevel reported a Phase 3 win for one of its programs in Parkinson’s disease.
Patients taking the biotech’s once-daily drug, called tavapadon, on top of the already approved …
-
Sage Therapeutics scraps plans for Parkinson's drug after mid-stage failure
17 Apr 2024 12:41 GMT
London: Sage Therapeutics said on Wednesday it will stop development of its experimental drug to treat Parkinson's disease after the treatment failed a mid-stage study, sending the company's shares tumbling 36 per cent before the bell.
Parkinson…